| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
L-Lysinamide dihydrochloride targets the process of DNA delivery rather than a specific biological receptor. It can be conjugated with cholesterol and L-ornithinamide to form a DNA delivery agent that binds and condenses DNA, facilitating its transfer into cells. It has also been reported to bind to the enzyme iridoid synthase, which is involved in the formation of imines and aldehydes in plant metabolism. However, its primary use is as a cationic molecule for nucleic acid complexation and non-viral gene delivery. It operates within the gene therapy and drug delivery pathways.
|
|---|---|
| ln Vitro |
In vitro, L-Lysinamide dihydrochloride is used to form complexes with DNA (lipoplexes or polyplexes) for transfection studies. A typical protocol: dissolve the compound in water or PBS to prepare a 10-50 mM stock. Mix with plasmid DNA at various N/P ratios (amine/phosphate ratio) and incubate for 15-30 min at room temperature to form complexes. Add to cells (e.g., HEK293, HeLa) in serum-free medium. After 4-6 h, replace with complete medium. Measure transfection efficiency after 24-48 h using a reporter gene assay (e.g., luciferase or GFP). No significant cytotoxicity is observed at N/P ratios up to 20. L-Lysinamide is less potent than polyethylenimine but provides a biodegradable alternative. DMSO is not used; compound is water-soluble.
|
| ln Vivo |
No in vivo activity data are available for L-Lysinamide dihydrochloride as a drug candidate. It is used as a reagent for in vitro DNA delivery studies. In some research contexts, it may be formulated with DNA for local administration in animal models to study gene delivery, but no detailed in vivo protocols are available in the sources. For research use only.
|
| Enzyme Assay |
Not applicable. L-Lysinamide dihydrochloride is a chemical reagent and analytical standard, not a drug candidate. For non-cellular characterization, a standard HPLC method can be used: dissolve the compound in water or 0.1% TFA to 1 mg/mL. Inject onto a C18 column (250×4.6 mm, 5 microm). Mobile phase: 0.1% TFA in water (A) and acetonitrile (B). Gradient: 0-30% B over 20 min. Flow rate: 1.0 mL/min, UV detection at 210 nm. Retention time is approximately 3-5 min. For LC-MS/MS, positive ESI mode, m/z 146 [M-2HCl+H]+ for the free base. Melting point: 222-224degC. Purity typically >98% (HPLC). No enzyme/receptor binding assays.
|
| Cell Assay |
For in vitro cell transfection assays, culture HEK293 or HeLa cells in DMEM with 10% FBS at 37degC, 5% CO2. Seed cells in 24-well plates (1×10⁵ cells/well) 24 h before transfection. Prepare L-Lysinamide dihydrochloride in water to a concentration of 1-10 mM. Prepare DNA solution (0.5-1 ug plasmid DNA in 50 uL Opti-MEM). Mix the compound with DNA at various N/P ratios (e.g., 5:1, 10:1, 20:1) and incubate for 15-30 min. Add the complexes to cells in serum-free medium. After 4-6 h, add 1 mL of complete medium (20% FBS) to each well. Incubate for 24-48 h. For GFP reporter, visualize by fluorescence microscopy. For luciferase, lyse cells and measure luminescence. Positive control: Lipofectamine 2000. Negative control: naked DNA. DMSO not used. All experiments in triplicate.
|
| Animal Protocol |
No in vivo animal studies are performed with L-Lysinamide dihydrochloride as a drug candidate. It is a chemical reagent for in vitro use. For research use only.
|
| ADME/Pharmacokinetics |
Not applicable. L-Lysinamide dihydrochloride is a chemical reagent, not a drug candidate; its pharmacokinetic properties are not characterized. If administered systemically, as a small cationic molecule (MW 218.12), it would likely be rapidly cleared renally and metabolized to lysine. For storage, powder at -20degC for up to 3 years, protected from light and moisture. Solubility: water (freely soluble), DMSO (slightly). Appearance: white to off-white solid powder. Melting point: 222-224degC. Purity >98% (HPLC).
|
| Toxicity/Toxicokinetics |
No formal toxicity data are available for L-Lysinamide dihydrochloride. In cell transfection assays, no significant cytotoxicity is observed at effective N/P ratios. L-Lysine and its derivatives are generally considered safe. Standard laboratory safety precautions for handling chemical reagents should be followed: avoid inhalation, ingestion, skin/eye contact; use PPE (gloves, lab coat, safety goggles); work in a fume hood. For research use only-not for human use. Dispose of waste according to local regulations for chemical waste.
|
| References | |
| Additional Infomation |
CAS: 51127-08-3. Molecular formula: C6H17Cl2N3O, molecular weight: 218.12. IUPAC name: (S)-2,6-diaminohexanamide dihydrochloride. Also known as L-lysine amide dihydrochloride. Appearance: white to off-white solid powder. Melting point: 222-224degC. Solubility: water (freely soluble), DMSO (slightly). Purity: >98% (HPLC). Storage: -20degC, protected from light and moisture. Use: DNA delivery reagent, peptide synthesis building block. Not for human use. For research only.
|
| Molecular Formula |
C6H17CL2N3O
|
|---|---|
| Molecular Weight |
218.12
|
| Exact Mass |
217.075
|
| CAS # |
51127-08-3
|
| Related CAS # |
L-Lysinamide; 32388-19-5
|
| PubChem CID |
20760365
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
12
|
| Complexity |
105
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(CCN)C[C@@H](C(=O)N)N.Cl.Cl
|
| InChi Key |
AIYVJLPYZQDCKV-XRIGFGBMSA-N
|
| InChi Code |
InChI=1S/C6H15N3O.2ClH/c7-4-2-1-3-5(8)6(9)10;;/h5H,1-4,7-8H2,(H2,9,10);2*1H/t5-;;/m0../s1
|
| Chemical Name |
(2S)-2,6-diaminohexanamide;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~229.23 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5846 mL | 22.9232 mL | 45.8463 mL | |
| 5 mM | 0.9169 mL | 4.5846 mL | 9.1693 mL | |
| 10 mM | 0.4585 mL | 2.2923 mL | 4.5846 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
